Usefulness of the preoperative administration of tegafur suppositories as alternative adjuvant chemotherapy for patients with resectable stage II or III colorectal cancer: A KODK4 multicenter randomized control trial

Oncology (Switzerland)

Volumn 83, Issue 1, 2012, Pages 16-23

  Okabayashi, Koji ^a   Hasegawa, Hirotoshi ^a   Watanabe, Masahiko ^c   Ohishi, Takashi ^b   Hisa, Akio ^d   Kitagawa, Yuko ^a  

^a KEIO UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^c KITASATO UNIVERSITY   (Japan)

^d Saitama Social Insurance Hospital   (Japan)

Author keywords

Colorectal cancer; Neoadjuvant chemotherapy; Randomized control trial; Tegafur suppository

Indexed keywords

FLUOROURACIL; FLUOROURACIL PLUS LEUCOVORIN; FOLINIC ACID; TEGAFUR; UFT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DISTANT METASTASIS; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; LAPAROTOMY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT COMPLIANCE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SUPPOSITORY; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREOPERATIVE CARE; PREOPERATIVE PERIOD; SUPPOSITORIES; SURVIVAL RATE; TEGAFUR;

EID: 84862486438     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000337574     Document Type: Article

References (22)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352-358. (Pubitemid 20042739)
3. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939-944.
4. O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, Wieand HS: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15: 246-250. (Pubitemid 27020580)
5. Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, Mayer RJ: Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 2005; 23: 8671-8678. (Pubitemid 46211510)
6. Andre T, Quinaux E, Louvet C, Colin P, Gamelin E, Bouche O, Achille E, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Lledo G, Raoul Y, Debrix I, Buyse M, de Gramont A: Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol 2007; 25: 3732-3738. (Pubitemid 47372615)
7. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the mosaic trial. J Clin Oncol 2009; 27: 3109-3116.
8. Haller DG, Cassidy J, Tabernero J, et al: Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (no16968): no impact of age on disease-free survival (DFS). 2010 Gastrointestinal Cancers Symposium: abstract 284.
9. Rousseau B, Chibaudel B, Bachet JB, Larsen AK, Tournigand C, Louvet C, Andre T, de Gramont A: Stage II and stage III colon cancer: Treatment advances and future directions. Cancer J 2010; 16: 202-209.
10. Ohwada S, Sato Y, Izumi M, Kashiwabara K, Ogawa T, Hamada K, Kawate S, Nakamura S: Preoperative tegafur suppositories for respectable rectal cancer: phase II trial. Dis Colon Rectum 2006; 49: 1602-1610. (Pubitemid 44796133)
11. Takahashi T, Horie H, Kojima O, Itoh M: Preoperative combined treatment with radiation, intraluminal hyperthermia, and 5-fluorouracil suppositories for patients with rectal cancer. Surg Today 1993; 23: 1043-1048. (Pubitemid 24007961)
12. Saito N, Sarashina H, Nunomura M, Koda K, Takiguchi N, Nakajima N: Clinical evaluation of nerve-sparing surgery combined with preoperative radiotherapy in advanced rectal cancer patients. Am J Surg 1998; 175: 277-282. (Pubitemid 28183549)
13. Heald RJ, Ryall RD: Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986; 1: 1479-1482. (Pubitemid 16095660)
14. Visser O, Bakx R, Zoetmulder FA, Levering CC, Meijer S, Slors JF, van Lanschot JJ: The influence of total mesorectal excision on local recurrence and survival in rectal cancer patients: a population-based study in greater amsterdam. J Surg Oncol 2007; 95: 447-454. (Pubitemid 46709387)
15. Ishii Y, Hasegawa H, Endo T, Okabayashi K, Ochiai H, Moritani K, Watanabe M, Kitagawa Y: Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer. Eur J Surg Oncol 2010; 36: 1061-1065.
16. Isomoto H, Tomita M, Sugimachi K, Ogawa M, Yamada K, Nakagoe T, Mori M, Takano S, Kakegawa T: Pre-and post-operative adjuvant chemotherapy in colorectal cancer. Int J Oncol 2003; 23: 1103-1108.
17. Kimoto M, Nagano H, Gunge N, Murei T, Iwamoto S, Seo Y, Yamamoto Y, Sano K: Serum concentration of 5-FU and tegafur (FT-207) after administration of tegafur (FT-207) suppository with the colostomy (in Japanese). Gan To Kagaku Ryoho 1987; 14: 2853-2858. (Pubitemid 18080510)
18. Arima S, Futami K, Yoshimura S, Shimura H: Distributions of tegafur in tissues of gastric adenocarcinoma patients: tissue uptakes and concentrations in plasma after oral and rectal administrations. Jpn J Clin Oncol 1989; 19: 237-241.
19. Okabayashi K, Hasegawa H, Ishii Y, Endo T, Ochiai H, Kubota T, Kitagawa Y: Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients. Cancer Chemother Pharmacol 2009; 63: 501-507.
20. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705.
21. Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K: Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 2010; 11: 853-860.
22. Pucciarelli S, Del Bianco P, Efficace F, Serpentini S, Capirci C, De Paoli A, Amato A, Cuicchi D, Nitti D: Patient-reported outcomes after neoadjuvant chemoradiotherapy for rectal cancer: a multicenter prospective observational study. Ann Surg 2011; 253: 71-77.